New‐generation anticancer drugs and medication‐related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy

Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonecrosis of the jaw. Multidisciplinary team management of these patients should be provided.

Detalles Bibliográficos
Autores principales: Guida, Agostino, Perri, Francesco, Ionna, Franco, Ascierto, Paolo A., Grimaldi, Antonio M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813008/
https://www.ncbi.nlm.nih.gov/pubmed/33489133
http://dx.doi.org/10.1002/ccr3.3418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813008/
https://www.ncbi.nlm.nih.gov/pubmed/33489133
http://dx.doi.org/10.1002/ccr3.3418

Ejemplares similares